Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR 16.50
-3.10 (-15.82%)
Last updated: Jul 28, 2026, 6:00 PM CET
Legend Biotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -236.57 | -282.6 | -158.1 | -520.2 | -445.72 | -407.2 |
Depreciation & Amortization | - | 28.9 | 21.4 | 18.5 | 18.39 | 13.92 |
Stock-Based Compensation | - | 64.6 | 68.9 | 47.7 | 34.34 | 20.16 |
Other Adjustments | - | 200.4 | -93 | 133.1 | 0.8 | 12.19 |
Change in Receivables | - | -5.7 | 93.8 | -99 | 50.32 | 24.59 |
Changes in Inventories | - | -4.5 | -17.2 | -12.7 | -13.89 | 0.05 |
Changes in Accounts Payable | - | 44.4 | 14.1 | -50.2 | 72.45 | 1.81 |
Changes in Accrued Expenses | - | 36.1 | 43.9 | -2.7 | 119.29 | 140.75 |
Changes in Income Taxes Payable | - | -18.4 | -1.6 | 0.3 | 3.71 | 0.56 |
Changes in Unearned Revenue | - | -40 | -49.7 | 100 | - | - |
Changes in Other Operating Activities | - | -123.4 | -66.5 | -8.1 | -40.95 | -5.28 |
Operating Cash Flow | -81.54 | -100.2 | -144 | -393.3 | -201.28 | -198.47 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | -28.6 | -14.1 | -20.1 | -20.93 | -42.2 |
Sale of Property, Plant & Equipment | - | - | - | - | - | 0 |
Purchases of Intangible Assets | - | -38.8 | -54.9 | -101.4 | -16.16 | -4.92 |
Purchases of Investments | - | -4,543 | -2,712 | -4,863 | -654.97 | -377.96 |
Proceeds from Sale of Investments | - | 5,320 | 1,928 | 5,069 | 613.71 | 230.08 |
Other Investing Activities | - | - | 2.5 | 8.9 | 1.25 | - |
Investing Cash Flow | 452.97 | 709.6 | -850.6 | 92.9 | -77.09 | -194.98 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Issuance of Common Stock | - | 3.3 | 9.7 | 795.2 | 380.57 | 628.08 |
Net Common Stock Issued (Repurchased) | - | 3.3 | 9.7 | 795.2 | 380.57 | 628.08 |
Other Financing Activities | - | -3.6 | -4 | -3.8 | -2.6 | -1.42 |
Financing Cash Flow | -0.92 | -0.3 | 5.7 | 791.4 | 377.98 | 626.66 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 3.38 | 6.1 | -2.1 | 0.7 | -2.51 | 0.03 |
Net Cash Flow | 200.25 | 615.2 | -991 | 491.7 | 99.6 | 233.22 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -81.54 | -128.8 | -158.1 | -413.4 | -222.21 | -240.66 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -7.16% | -12.52% | -25.20% | -145.00% | -189.91% | -349.67% |
Free Cash Flow Per Share | -0.44 | -0.70 | -0.86 | -2.35 | -1.40 | -1.71 |
Levered Free Cash Flow | -250.27 | -402.3 | -246.7 | -493.3 | -308.29 | -293.98 |
Unlevered Free Cash Flow | -132.97 | -248.86 | -416.2 | -501.17 | -297.47 | -293.09 |